PCI, the Antianginal'Pill': ORBITA-2 in Detail PCI, the Antianginal'Pill': ORBITA-2 in Detail
Michelle O ' Donoghue interviews the sham PCI controlled trial investigators on the role of stents in the management of stable angina in light of both ORIBTA studies.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 15, 2023 Category: Cardiology Tags: Cardiology Commentary Source Type: news
Low-Salt Diet Cut BP by 6 mm Hg in 1 Week: CARDIA-SSBP Low-Salt Diet Cut BP by 6 mm Hg in 1 Week: CARDIA-SSBP
The blood pressure reduction brought about by the low-sodium diet may be comparable to that produced by a single antihypertensive medication.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 15, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
ARTESIA Doesn't Answer a Common Question in Cardiology ARTESIA Doesn't Answer a Common Question in Cardiology
The trial on apixaban vs aspirin in subclinical atrial fibrillation did not provide an easy answer on whether to anticoagulate patients with these common arrhythmias, writes John Mandrola, MD.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 15, 2023 Category: Cardiology Tags: Cardiology Commentary Source Type: news
GLP-1 Drugs Reduced Patient A1c Levels, Need for Other Drugs GLP-1 Drugs Reduced Patient A1c Levels, Need for Other Drugs
In some cases, the addition of GLP-1 agonists allowed clinicians to deprescribe other medications such as insulin and sulfonylureas.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 15, 2023 Category: Cardiology Tags: Family Medicine/Primary Care News Source Type: news
Dual Energy Conversion Safe, Reliable for AF With Obesity Dual Energy Conversion Safe, Reliable for AF With Obesity
In patients with obesity, dual energy cardioversion is more reliable and just as safe as conventional single energy cardioversion as an initial strategy in AF, a new study shows.MDedge News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 14, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
GLP-1 RAs: How to Manage Real-World GI Complications GLP-1 RAs: How to Manage Real-World GI Complications
Although GLP-1 receptor agonists are transforming the treatment of diabetes and obesity, gastroenterologists increasingly are being called upon to manage the side effects of these medications.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 14, 2023 Category: Cardiology Tags: Gastroenterology News Source Type: news
Impressive Bleeding Profile With Factor XI Inhibitor in AF Impressive Bleeding Profile With Factor XI Inhibitor in AF
Further details from the phase 2b AZALEA trial of the factor XI inhibitor abelacimab show significant reductions in major and clinically relevant nonmajor bleeding vs rivaroxaban for patients with AF.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 13, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
Is It Time for Cardiologists to Treat Obesity? Is It Time for Cardiologists to Treat Obesity?
Cardiologists Michelle O ' Donoghue and Nicholas Marston discuss the"game changer" trial at AHA showing that GLP-1 agonist semaglutide reduced CV events in patients with ASCVD and overweight/obesity.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 13, 2023 Category: Cardiology Tags: Cardiology Commentary Source Type: news
Pregnancy in Rheumatic Disease Quadruples CVE Risk Pregnancy in Rheumatic Disease Quadruples CVE Risk
Pregnant patients with lupus and concomitant APS had an 18-fold higher risk for a cardiovascular event during and up to 6 weeks postpartum than did pregnant individuals without these conditions.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 13, 2023 Category: Cardiology Tags: Rheumatology News Source Type: news
Better Postpartum BP Control With Self-Monitoring: POP-HT Better Postpartum BP Control With Self-Monitoring: POP-HT
Self-monitoring blood pressure during the early postpartum period resulted in lower BPs and could prevent later cardiovascular events in women with hypertensive pregnancies, new research suggests.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 13, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
Apixaban Cuts Stroke But Ups Bleeding in Subclinical AF Apixaban Cuts Stroke But Ups Bleeding in Subclinical AF
Further analyses from the ARTESIA study and the previous NOAH-AFNET 6 trial are needed to try to identify groups where the benefit may outweigh the risk, researchers say.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 12, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
Potential Dapagliflozin Benefit Post-MI Is Not a'Mandate'Potential Dapagliflozin Benefit Post-MI Is Not a'Mandate '
A registry trial of SGLT-2 inhibition in low-risk patients after an MI showed some benefit in preventing future events, but a larger study would be warranted to further validate the signal.MDedge News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 12, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
Angioplasty Finally Proven Beneficial in Stable Angina Angioplasty Finally Proven Beneficial in Stable Angina
The randomized ORBITA-2 trial, unlike the preceding ORBITA trial, shows benefit for percutaneous coronary intervention in patients with stable angina.MDedge News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 11, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
Semaglutide'A New Pathway' to CVD Risk Reduction: SELECT Semaglutide'A New Pathway' to CVD Risk Reduction: SELECT
The weight loss drug showed a consistent reduction in major cardiovascular events over a 3-year follow up in patients with a history of heart disease who were overweight or obese.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 11, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
Nov 10 2023 This Week in Cardiology Nov 10 2023 This Week in Cardiology
Renal denervation, a potential deadly decision in the ED, GLP-1 agonists, and an AHA preview are the topics John Mandrola, MD, discusses in this week ’s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 11, 2023 Category: Cardiology Tags: Cardiology Commentary Source Type: news
